Clinical Trial Update: Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

View source ↗

Summary

Pfizer's Oxbryta (voxelotor) product registry observational study in individuals with sickle cell disease was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Oxbryta (voxelotor)

Snippet

Sponsor: Pfizer | Conditions: Sickle Cell Disease | Status: TERMINATED | Results posted: 2025-12-31